bearish
Changchun High & New Tech (000661.CH) - Logic Change?
179 Views16 Aug 2021 09:08
The article analyzed Changchun High & New Tech in terms of its 2021/1H financial results,media exposure of growth hormone abuse, possibility of volume-based purchase on growth hormone and the outlook.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- Shanghai MicroPort MedBot Group (2252.HK) - Optimistic About the Outlook08 Feb 2022
- Anke Biotechnology (300009CH) Vs Changchun High & New Tech (000661CH)-Growth Hormone VBP and Outlook03 Feb 2022
- Pre-IPO CANbridge Pharmaceuticals - Insights on Products, Pipeline and the Concerns17 Aug 2021
- Changchun High & New Tech (000661.CH) - Insights on Recent Pullback & The Future Business Outlook27 May 2021
- Pre-IPO Shanghai HeartCare Medical Technology - Promising Market but Fierce Competition31 Mar 2021
- I-Mab (IMAB US) - Insights On Core Products TJC4, TJ202 and TJ10129 Mar 2021
x